Previous 10 | Next 10 |
2023-08-23 13:00:00 ET Summary Geron aims for FDA approval of imetelstat in June 2024 for hematologic malignancies, targeting an H1 2024 launch. Recent FDA decision for standard review of imetelstat suggests caution and potential regulatory challenges. Geron's financial health...
2023-08-22 10:00:48 ET Gainers: Fulcrum Therapeutics ( FULC ) +55% . Renovaro Biosciences ( RENB ) +18% . ProMIS Neurosciences ( PMN ) +17% . cbdMD ( YCBD ) +9% . 60 Degrees Pharmaceuticals ( SXTP ) +7% . Losers: Emergent BioSo...
2023-08-22 08:26:12 ET More on Geron Geron Corporation ( GERN ) Q2 2023 Earnings Call Transcript Geron Corporation 2023 Q2 - Results - Earnings Call Presentation Geron Stock: These Prices Are Unlikely To Return Geron: Awaiting Marketing Approval And Role ...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Applica...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has accepted the filing of Geron’s New Drug Application (NDA) for imetelstat, its first-in-class telomerase inhibitor, for the treatm...
2023-08-03 23:30:27 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q2 2023 Earnings Call Aug 03, 2023 , 4:30 p.m. ET Aron Feingold Continue reading For further details see: Geron (GERN) Q2 2023 Earnings Call Transcript
2023-08-03 21:23:05 ET Geron Corporation (GERN) Q2 2023 Results Earnings Conference Call August 3, 2023, 04:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman of the Board, President ...
2023-08-03 16:35:02 ET Geron press release ( NASDAQ: GERN ): Q2 GAAP EPS of -$0.29 misses by $0.20 . As of June 30, 2023, the Company had $400.2 million in cash, cash equivalents, restricted cash and marketable securities. For further details see: Geron GAAP ...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its second quarter 2023 financial results on Thursday, August 3, 2023 at 4:00 p.m. Eastern Time via press release, which will be available on the Company’s website at w...
2023-07-18 16:47:08 ET Summary After decades of work and delay, Geron Corporation is finally approaching its first approval. That should be done by about H1 2024, and although the stock looks properly valued based on revenue projections, there are other factors in play. One of...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...